Ashley Watson
Family · Greenwich, NYNPI 1417241266
Payments from drug & device makers
Across 96 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$300
- Novo Nordisk$259
- GSK$245
- Astellas Pharma US Inc$188
- Lilly USA, LLC$174
- Takeda Pharmaceuticals U.S.A., Inc.$148
- plus $549 from 9 others
What the payments were for
- Food & beverage$1,862100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $300 |
| Novo Nordisk | 14 | $259 |
| GSK | 14 | $245 |
| Astellas Pharma US Inc | 8 | $188 |
| Lilly USA, LLC | 10 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $148 |
| Amarin Pharma, Inc. | 8 | $148 |
| AstraZeneca | 8 | $118 |
| Pfizer | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| AbbVie | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Boehringer Ingelheim | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$1,862 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $59,106 |
| TrulicityDulaglutide | 43 | $49,871 |
| EliquisApixaban | 52 | $46,466 |
| JardianceEmpagliflozin | 41 | $39,984 |
| FarxigaDapagliflozin Propanediol | 36 | $32,727 |
| JanuviaSitagliptin Phosphate | 19 | $27,162 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $18,621 |
| InvokanaCanagliflozin | 17 | $14,586 |
| TradjentaLinagliptin | 16 | $12,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $11,985 |
| RybelsusSemaglutide | 12 | $11,781 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $11,296 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $10,425 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,513 |
| LinzessLinaclotide | 13 | $9,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $259 | $70,88766 claims |
| Boehringer IngelheimJardiance, Tradjenta | $23 | $52,18557 claims |
| Lilly USA, LLCTrulicity | $174 | $49,87143 claims |
| PfizerEliquis | $90 | $46,46652 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $118 | $42,24151 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $245 | $30,60651 claims |
| Johnson & JohnsonInvokana | $300 | $14,58617 claims |
| AbbVieLinzess, Synthroid | $42 | $13,01672 claims |
| Astellas Pharma US IncMyrbetriq | $188 | $7,33917 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $148 | $5,83712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.
Other family in Greenwich
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.